Slide 1: Devyser Earnings call Q2 2026
Devyser Earnings call Q2 2026 July 20, 2026
Slide 2: Today's presenters
Today’s presenters Jan Wahlström Sabina Berlin CEO CFO
Slide 3: Q2 2026: temporary revenue setback, continued profitable growth
Q2 2026: temporary revenue setback, continued profitable growth
Slide 4: Q2 highlights
Q2 highlights · Weak sales in transplant due to inventory buildup at our largest distributor o Transplant volumes growing well above target – impact is lab onboarding timing, not demand o Will impact distributor sales through 2026, normalizing from 2027 · Underlying gross margin ~80% YTD (ex. transp
Slide 5: Growth continues in core segments
Growth continues in core segments · Good development in hereditary product line o Direct markets and other distributor markets continue to grow, despite inventory buildup at our largest distributor o Won MSEK 8.9 tender in Italy, strengthening market position
Slide 6: MolDx progress
MolDx progress · MolDx application for kidney transplant follow up as a service in the US ongoing · Estimated approval before the end of the year · Preparations ongoing for commercialization and channel strategy ahead of approval
Slide 7: Second quarter 2026
Second quarter 2026
Slide 8: Second quarter
Second quarter ▪ Revenue • Sales 60.2 MSEK (67.4 MSEK) • Growth -10.7%, F/X adjusted -9.7% 8
Slide 9: Rolling 12 months net sales
Rolling 12 months net sales SEK million 300 250 200 150 100 50 0 9
Slide 10: Sales by region
Sales by region % of Q2 % of Q2 % Growth Q2 2026 Q2 2025 2026 2025 QoQ EMEA 52,7 51,3 87,5% 83,5% 2,7% Asia-Pacific 2,3 1,8 3,8% 2,7% 25,7% North and South 5,2 14,3 8,6% 13,4% -63,4% America Total 60,2 67,4 100,0% 100,0% -10,7% 10
Slide 11: Sales by sales channel
Sales by sales channel % of Q2 % of Q2 % Growth Q2 2026 Q2 2025 2026 2025 QoQ Direct sales 48,5 42,6 80,6% 63,2% 14,0% Distributor sales 11,7 24,9 19,4% 36,9% -53,0% Total 60,2 67,4 100,0% 100,0% -10,7% 11
Slide 12: Second quarter
Second quarter ▪ Revenue • Sales 60.2 MSEK (67.4 MSEK) • Growth -10.7%, F/X adjusted - 9.7% ▪ Gross margin 76.0% (84.2%) 12
Slide 13: Second quarter
Second quarter ▪ Revenue • Sales 60.2 MSEK (67.4 MSEK) • Growth -10.7%, F/X adjusted - 9.7% ▪ Gross margin 76.0% (84.2%) ▪ EBIT • 0.5 MSEK (5.5) 13
Slide 14: Second quarter
Second quarter ▪ Revenue • Sales 60.2 MSEK (67.4 MSEK) • Growth -10.7%, F/X adjusted - 9.7% ▪ Gross margin 76.0% (84.2%) ▪ EBIT • 0.5 MSEK (5.5) ▪ Cash • 81.0 MSEK in liquidity • Operative cash flow +12.3 MSEK 14
Slide 15: Highlights Q2 and Commercial outlook
Highlights Q2 and Commercial outlook
Slide 16: Q2 commercial recap
Q2 commercial recap ▪ A second quarter with good development in hereditary sales but a disappointment in transplant products ▪ Strong development in US sales with our direct business ▪ Launched One Lambda Devyser Chimerism Plus with Thermo Fisher, strengthening our competitive position ▪ Won a – ten
Slide 17: Reagent rental deals
Reagent rental deals · In several tenders we see a competitive advantage with our Illumina reagent rental agreement · Several opportunities in the pipeline · Normal contract length is 3-5 years
Slide 18: Update on Thermo Fisher Scientific
Update on Thermo Fisher Scientific ▪ Since quarter-end, launched One Lambda Devyser Chimerism Plus with Thermo Fisher – a next-generation chimerism monitoring solution that reduces workflow-related error risk while improving lab efficiency and usability ▪ Sales in Q2 and the rest of the year weak du
Slide 19: North America update
▪ Devyser Genomic Laboratories ▪ Cyted collaboration is following plan ▪ Sales at CLIA lab has solid performance ▪ CFTR and Thalassemia drove growth in both the quarter North and the first half year ▪ Direct sales continue to build stronger leads pipeline America update
Slide 20: Europe
• The Illumina agreement broadens our play in Europe and strengthens our position, it is a framework agreement which enables a broader future collaboration. We have multiple opportunities to get reagent rental agreements in place. Europe • The new version of Thalassemia continues to see good growth
Slide 21: Going forward
Going forward • Temporary drop in transplant sales due to distributor inventory buildup – underlying demand remains solid • Still growing markedly faster than the underlying market in hereditary portfolio • Continued profitable growth thanks to improved organizational efficiency • Sharpened cost foc
Slide 22: Q&A
O&A Dvysr.
Slide 23: Thank you!
Thank you! Connect with us www.devyser.com A black background with a black square Description automatically generated with medium confidence A black background with a black square Description automatically generated with medium confidence A black background with a black square Description automatica